SCHEMBL5542264

SCHEMBL5542264

O=C(OCN1C(=O)c2ccccc2C1=O)c1cc(/N=N/c2ccc(O)c(C(=O)OCN3C(=O)c4ccccc4C3=O)c2)ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.60
MEN1 O00255 6/20 0.60
HSD17B10 Q99714 3/20 0.49
TSHR P16473 2/20 0.49
POLB P06746 1/20 0.47
PDE4A P27815 1/20 0.44
BLVRB P30043 1/20 0.44
KDR P35968 1/20 0.44
HTT P42858 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
ALOX15 P16050 1/20 0.42
ALDH1A1 P00352 2/20 0.42
APP P05067 1/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ESR1 P03372 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536153 0.88 SMN1; SMN2 (0.56) KMT2AMEN1HSD17B10TSHRALDH1A1
SCHEMBL10085967 0.83 KMT2A (0.62) KMT2AMEN1HSD17B10TSHRPOLB
SCHEMBL5534499 0.82 KMT2A (0.71) KMT2AMEN1HSD17B10TSHRPOLB
SCHEMBL576998 0.81 SLC7A11 (0.65) KMT2AMEN1TSHRBLVRBALDH1A1
SCHEMBL5542353 0.79 NR1H3 (0.52) KMT2AMEN1ALDH1A1TDP1ESR1
SCHEMBL5539344 0.79 NR1H3 (0.47) KMT2AMEN1PDE4ABLVRBKDR
SCHEMBL5540729 0.79 NR1H3 (0.50) POLBTDP1
SCHEMBL5541967 0.77 NR1H3 (0.54) ALDH1A1
SCHEMBL10085968 0.74 NR1H3 (0.43) KMT2AMEN1PDE4ABLVRBKDR
SCHEMBL12931735 0.73 CA12 (0.59) KMT2AMEN1HSD17B10TSHRPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES TNF, PER2, CRY1 KMT2A 2382/4885MEN1 3050/4885HSD17B10 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.